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Abstract
The importance of β-chemokines (or CC chemokine ligands – CCL) in the development of
inflammatory lesions in the central nervous system of patients with multiple sclerosis and rodents
with experimental allergic encephalomyelitis is strongly supported by descriptive studies and
experimental models. Our recent genetic scans in families identified haplotypes in the genes of
CCL2, CCL3 and CCL11-CCL8-CCL13 which showed association with multiple sclerosis.
Complementing the genetic associations, we also detected a distinct regional expression regulation
for CCL2, CCL7 and CCL8 in correlation with chronic inflammation in multiple sclerosis brains.
These observations are in consensus with previous studies, and add new data to support the
involvement of CCL2, CCL7, CCL8 and CCL3 in the development of inflammatory demyelination.
Along with our own data, here we review the literature implicating CCLs and their receptors
(CCRs) in multiple sclerosis and experimental allergic encephalomyelitis. The survey reflects that
the field is in a rapid expansion, and highlights some of the pathways which might be suitable to
pharmaceutical interventions.
Introduction
Multiple sclerosis (MS) is a disabling disease of the central
nervous system (CNS) with features of autoimmunity and
neurodegeneration. Although the identity of primary anti-
genic determinant(s) is uncertain, an interaction between
β-chemokine ligands and their receptors plays a central
role in the recruitment and retention of inflammatory
cells in the CNS. Thus, both the disease relevant chemok-
ine ligands and their receptors represent potential thera-
peutic targets in MS.
Chemokines are a group of small, structurally related che-
moattractant molecules that regulate cell trafficking
through interactions with a set of receptors [1]. Evidence
suggests that the migration of autoreactive immune cells
via the blood-brain barrier (BBB) is an early and critical
process during the development of inflammatory CNS
lesions of experimental allergic encephalomyelitis (EAE)
and MS, and that this transmigration is regulated by
chemokines produced at the blood-brain barrier (BBB)
and in the CNS. Subcellular signals induced by the bind-
ing of chemokines to their G-protein-coupled receptors
leads to an increased avidity of integrins on leukocytes to
their corresponding receptors on endothelial cells, fol-
lowed by a facilitated migration of leukocytes towards the
chemokine gradient in the CNS [2,3].
In addition to chemotaxis, chemokines are also involved
in the regulation of T cell differentiation, apoptosis, cell
cycle, angiogenesis and metastatic processes. Further,
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chemokines can control the generation of soluble inflam-
matory products such as free radicals, nitric oxide,
cytokines and matrix metalloproteases [1,4]. Considering
the predominantly T helper type 1 (TH1) mediated proc-
ess of inflammatory demyelination and the TH2 driven
suppression of inflammation, the differential effects of
various chemokines on TH1 or TH2 polarization may
have particular significance. The currently known, approx-
imately 50 chemokine genes in humans are divided into
four subfamilies on the basis of characteristic patterns of
cysteine residues close to the N-terminal end of the prod-
ucts. The CC chemokine ligand family (CCL) (also known
as β-chemokines or Small Cytokine Group A – SCYA in
mice) is characterized by two adjacent cysteines, while the
CXC (SCYB) and CX3C (SCYD or fractalkine) chemokine
families have one or three intervening amino acids,
respectively, between the two cysteines. In the XC family
(SCYC or lymphotactin), only one cysteine is present [1].
All four classes of chemokines play important roles in the
immune inflammatory network, but because of the com-
plexity of interactions, here we only discuss the CC chem-
okine family. In humans, there are 27 CC chemokines,
most of which including CCL2, CCL7, CCL11, CCL8,
CCL13, CCL1, CCL5, CCL16, CCL14, CCL15, CCL23,
CCL18, CCL3 and CCL4, respectively, are encoded as a
cluster within chromosome 17q11. The genes for CCL27,
CCL19 and CCL21 are located within chromosome 9p13,
while CCL17 and CCL22 are encoded at 16q13. The
remaining CCL genes can be found on chromosome 2 and
7 [1].
A functional classification was also proposed to distin-
guish between lymphoid and inflammatory chemokines
[1,5]. Lymphoid or homeostatic chemokines (e.g. CCL21,
CCL25, CXCL13) are constitutively expressed and control
physiologic trafficking of cells of the adoptive immune
system during hematopoiesis and immunosurveillance.
Inflammatory or induced chemokines (e.g. CCL2, CCL3,
CCL5, CCL7, CCL8, etc...) are transcriptionally regulated
during inflammation and mediate the recruitment of
inflammatory cells to target tissues.
The effects of chemokines are mediated by G-protein cou-
pled receptors with seven-transmembrane-domains.
Chemokine receptors tend to bind multiple chemokine
ligands and vice versa. However, the biologically most
efficient interaction often occurs between a receptor and
its primary ligand (e.g. CCL2 – CCR2). The receptor bind-
ing involves high affinity interactions and signal transduc-
tion initiated by the dissociation of G-protein complex
into Gα and Gβγ subunits. Gα induces the activation of
the phosphoinositidine 3-kinase pathway, while the Gβγ
subunits activate phospholipase C and induce Ca2+ influx
and protein kinase C activation. The involvement of MAP
kinases as well as JAK/STAT signaling also has been shown
[6]. As of today, 10 CC chemokine receptors (CCRs), 6
CXCRs, one CX3CR1 and one XCR1 are known [1,6].
This review focuses on the immunomodulatory effects of
the β-chemokine or CCL family in EAE and MS. CC chem-
okines predominantly are involved in the recruitment of
monocytes / macrophages and dendritic cells (monocyte
chemoattractant proteins -MCP-1 [CCL2], MCP-2 [CCL8],
MCP-3 [CCL7], MCP-4 [CCL13] and macrophage inflam-
matory proteins – MIP-1α [CCL3] and MIP-1β [CCL4]),
and to lesser degrees, T lymphocytes and NK cells (MCP
and MIP chemokines, regulated upon activation normal T
cell expressed and secreted cytokine [RANTES]) or occa-
sionally other cell types (e.g. eosinophil chemotactic pro-
tein – eotactin [CCL11]) into inflammatory lesions of MS.
Genetic evidence for the involvement of β-
chemokines in multiple sclerosis
A meta-analysis of raw genotype data from three genome
scans in MS families revealed the highest nonparametric
linkage (NPL) score = 2.58 at 17q11 [7]. Among several
candidate genes (e.g. NOS2A, OMG, NF1), a cluster of
evolutionarily closely related β-chemokine genes [CCL2,
CCL7, CCL11, CCL8, CCL13, CCL1, CCL5, CCL16,
CCL14, CCL15, CCL23, CCL18, CCL3 and CCL4, respec-
tively] is encoded within a 1.85 Mb segment of 17q11.2-
q12. Our recent linkage disequilibrium mapping con-
fined the susceptibility regions to 3–30 kb haplotypes
defined by single nucleotide polymorphisms (SNP)
within the genes of CCL2, CCL11-CCL8, CCL8-CCL13,
CCL13 and CCL3 [8]. A second study is under way to con-
firm and further refine the MS relevant haplotypes, and
then, to identify the specific disease causing nucleotide
variants in an independent set of families.
Within the orthologous mouse chromosome 11, two
quantitative trait loci (QTL), eae6 and eae7 were identi-
fied. While these loci control the severity and duration of
EAE, eae7 is also a susceptibility locus for the monophasic
remitting / non-relapsing subtype of the disease [9].
Sequence polymorphisms within the genes of Scya1 (TCA-
3 or CCL1), Scya2 (MCP-1 or CCL2) and Scya12 (MCP-5
or CCL12) in eae7 showed striking segregations among
mouse strains resistant or susceptible to EAE.
Using an advanced intercross line in combination with
congenic strains, Jagodic et al. [10] fine mapped eae18 and
identified two adjacent QTLs, eae18a and eae18b, on the
rat chromosome 10 in a myelin-oligodendrocyte glyco-
protein (MOG)-induced, chronic relapsing EAE. The
eae18b locus is also orthologous to human chromosome
17q11 and encodes a cluster of β-chemokine genes.
The recognition of β-chemokine genes as susceptibility
and quantitative trait loci in mouse and rat EAE along
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with the human data revealing the β-chemokine gene
cluster as a susceptibility locus in MS, strongly suggest the
involvement of β-chemokine variants in the development
of inflammatory demyelination.
CCL and CCR molecules in inflammatory 
demyelination
Experimental allergic encephalomyelitis
EAE is a valuable model for studying the effector arm of
immune response in inflammatory demyelination. It can
be induced in susceptible strains of inbred and outbred
species by active immunization with myelin related pro-
teins and their peptides (myelin basic protein – MBP, pro-
teolipid lipoprotein – PLP, myelin oligodendrocyte
glycoprotein – MOG) emulsified in Freund's complete
adjuvant along with intravenous Pertussis toxin, or with a
passive transfer of myelin antigen specific T cell lines into
naïve recipients. Using various immunization protocols,
acute and chronic relapsing (CR-EAE) models have been
developed. In both the active immunization and the pas-
sive transfer models of EAE, the efferent arm of immune
response involves the migration of monocytes / macro-
phages, dendritic cells and activated myelin-antigen-spe-
cific T lymphocytes from the blood circulation into the
CNS, where a reactivation of specific lymphocytes by mye-
lin-antigen-presenting dendritic cells, macrophages and
residential microglia takes place, and the sequential devel-
opment of perivascular and parenchymal inflammation is
followed by demyelination and neuronal degeneration.
Encephalitogenic T lymphocytes have CD4+ TH1 pheno-
type characterized by the production of interleukin (IL)-2
and interferon-γ. TH2 lymphocytes producing IL4, IL5,
IL6 and IL10 cytokines are involved in the counter-regula-
tion of TH1 effects, and promote clinical recovery. The
TH1 / TH2 polarization is regulated by cytokines and
chemokines. The transmigration of immune competent
cells via the blood-brain barrier is aided by a temporal and
spatial regulation of adhesion molecules on T lym-
phocytes and their counterparts on endothelial cells, and
of chemokine ligands and their receptors in the residential
CNS and hematogenous mononuclear cells.
One of the most comprehensively studied CC chemok-
ines in inflammatory demyelination is MCP-1 (CCL2).
MCP-1 (CCL2) influences both innate immunity through
its chemoattractant effect on monocytes / macrophages,
and adaptive immunity through its effect on T cell polari-
zation towards the TH2 subtype [11]. CCL2 primarily acts
via the CCR2 receptor [1].
MIP proteins have both chemotactic and proinflamma-
tory effects, but also promote homeostasis [6]. The MIP-1
family includes MIP-1α (CCL3), MIP-1β (CCL4), MIP-1δ
(CCL9/10) and MIP-1γ (CCL15) that are produced by
macrophages, microglia, astrocytes, dendritic cells and
lymphocytes. These MIP-1 molecules act via CCR1, CCR3
and CCR5 expressed by lymphocytes and monocytes.
MIP-1 proteins also regulate immune response by modu-
lating T cell differentiation. The CCL3 and CCR5 interac-
tion promotes polarization towards the TH1 subtype.
Our understanding concerning the role of these CC chem-
okines and their receptors in inflammatory demyelination
was greatly advanced by studies in the EAE model. In
mice, the increased expression of MCP-1 (CCL2) by CNS
immune cells is closely associated with the clinical activity
of EAE [12-14]. Some studies, however, suggest that the
presence of leukocytes is necessary for the production of
CCL2 by astrocytes, as the expression of CCL2 prior to the
accumulation of inflammatory mononuclear cells has not
been observed in the CNS. Substantial MCP-1 (CCL2)
expression may only occur in the late phase of acute dis-
ease and in the relapsing phases of CR-EAE. It was there-
fore postulated, that CCL2 is involved in the
amplification rather than in the initiation of EAE [4]. In
contrast, the MIP-1α (CCL3) expression correlates with
the severity of acute disease and also is elevated during
relapses in CR-EAE. RANTES (CCL5) is expressed in the
CNS throughout the course, but does not correlate with
the severity of acute or CR-EAE [13].
Jee et al [15] compared the histological features and MCP-
1 (CCL2) and CCR2 expression levels in the lesions of
Lewis rats during the acute attack of monophasic EAE and
during the first two clinical events of CR-EAE. In concert
with the mouse data [4,13], not only higher numbers of
macrophages infiltrated the spinal cord during the first
and second attacks of CR-EAE as compared to those at the
peak of acute EAE in these rats, but the expression of MCP-
1 (CCL2) was also significantly higher in the lesion of CR-
EAE as compared to that of acute EAE. Similarly, CCR2,
the main receptor for CCL2, was expressed by astrocytes,
macrophages and T cells in higher amounts during CR-
EAE than at the peak of acute EAE. This observation con-
firmed the role of CCL2 – CCR2 interaction in the devel-
opment of relapses.
Youseff et al [16] observed an increased mRNA transcrip-
tion not only for MCP-1 (CCL2), but also for MIP-1α
(CCL3) and MIP-1β (CCL4) at the onset of EAE in rat
brains. MIP-1α (CCL3) and MCP-1 (CCL2) declined in
two days even though the clinical disease further pro-
gressed. MIP-1β (CCL4) mRNA declined in correlation
with the clinical recovery. RANTES (CCL5) mRNA, in con-
trast, increased in the brains only after recovery. The full
length, reverse transcribed and PCR amplified DNA prod-
uct for each of these four CCL molecules was transferred
into a plasmid vector and injected as naked DNA vaccine
into rats. Both the transcription of a relevant chemokine
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and the induced antibody response against it was moni-
tored. The in vivo immune response to these CCL mole-
cules differentially influenced the evolution of EAE. MIP-
1α (CCL3) and MCP-1 (CCL2) DNA vaccines prevented
EAE, while MIP-1β (CCL4) aggravated the disease and
RANTES (CCL5) did not have an effect on the course of
EAE. This study emphasizes the importance of CCL2 and
CCL3 in the development of active EAE in rats.
CCL1 also attracted attention in EAE. Teutscher et al [9]
identified eae7 encoding CCL1 and other chemokines as a
susceptibility locus and QTL in murine EAE. SNPs in
CCL1 differentially segregated in mouse strains suscepti-
ble or resistant to EAE. mRNA molecules for both CCL1
and its receptor CCR8 were detected in spinal cord lesions
of EAE, in correlation with the expression of tumor necro-
sis factor (TNF)-α by inflammatory leukocytes [17-19]. As
both CCL1 and CCR8 were detected in microglia, an auto-
crine signaling mechanism was postulated. CCR8 (-/-)
mice showed marked delay in the onset and reduced
severity of EAE as compared to controls. Leukocyte infil-
tration in the spinal cord was not diminished in the CCR8
(-/-) mice, suggesting that that a defective microglial acti-
vation might have altered the clinical phenotype.
Recent studies addressed the role of chemokines at the
blood-brain barrier. Using intravital fluorescence videom-
icroscopy, Vajkoczy et al [20] demonstrated that the inter-
action between encephalitogenic T cells and endothelial
cells of the BBB involves α4-integrin (VLA-4) which medi-
ates a G-protein-independent capture (arrest) followed by
G-protein-dependent adhesion strengthening of circulat-
ing T cells to VCAM-1 on endothelial cells. Postulating the
involvement of chemokines in the integrin-mediated
arrest of autoreactive T cells at the BBB, the investigators
[3] subsequently aimed to identify the specific chemok-
ines by performing in situ hybridization and immunohis-
tochemistry on brain and spinal cord sections of mice
with EAE. Constitutive expression of the lymphoid chem-
okine called EBV-induced molecule 1 ligand chemokine
(ELC) / CCL19 in a subpopulation of CNS venules and
induced expression of the secondary lymphoid chemok-
ine (SLC) / CCL21 in inflamed CNS venules was detected.
CCR7, the common receptor for these two chemokines
was expressed on a subpopulation of cells in the perivas-
cular cuffs. Encephalitogenic T cells in vitro showed
expression of CCR7 and CXCR3, the alternative receptor
for CCL21, and chemotaxed towards both CCL19 and
CCL21 in a concentration-dependent and a Pertussis
toxin-sensitive manner similar to naïve T cells. Functional
deletion of CCR7 and CXCR3 or immune blockade of
CCL19 and CCL21 reduced the binding of encephalito-
genic T cells to inflamed venules in frozen brain sections.
Altogether, these data suggest that CCL19 and CCL21 are
expressed in cerebral endothelial cells and are involved in
α4-integrin mediated adhesion strengthening of autoreac-
tive T cells and subsequently of other inflammatory cells
to the endothelial layer of the BBB. These molecular inter-
actions may lead to permanent inflammatory cell immi-
gration into the CNS in chronic autoimmune disease.
CCL20 or MIP-3α (exodus-3 / LARC) is a chemokine
active on dendritic cells and lymphocytes that express
CCR6 [1]. Serafini et al [21]demonstrated the occurrence
of dendritic cells in the spinal cord of mice immunized
with the PLP139–151 peptide. Although dendritic cells
were present during early acute, chronic and relapsing
EAE, most prominent infiltration of spinal cord by mature
dendritic cells was noted in relapsing disease. In all stages
of EAE, CCL20 and CCR6 were upregulated in the CNS.
This study emphasizes the importance of dendritic cells in
antigen presentation and T cell restimulation, and links
the immigration of dendritic cells to the expression of
CCL20 in the CNS during EAE.
CCL22 or macrophage-derived chemokine (MDC) is che-
moattractant for monocytes, dendritic and NK cells, and T
lymphocytes of the TH2 subtype. MDC / CCL22 acts via
CCR4 which is preferentially detected on TH2 type, mem-
ory and regulatory T cells [22]. While MDC / CCL22 is
considered to be predominantly involved in TH2 medi-
ated immunity, Columba-Cabezas et al [22] demon-
strated mRNA expression for MDC / CCL22 in the CNS of
mice with relapsing-remitting and chronic-relapsing EAE
induced by PLP139–151 or whole spinal cord homoge-
nate. Immunohistochemistry demonstrated that MDC /
CCL22 is produced by infiltrating leukocytes and residen-
tial microglia, while CCR4 is expressed by infiltrating leu-
kocytes. In vitro activation of microglia resulted in
secretion of bioactive MDC / CCL22 that induced chemo-
taxis of TH2 lymphocytes. This study concludes that MDC
/ CCL22 produced by microglia may play a role in a TH1
mediated CNS inflammation by inducing the homing of
TH2 regulatory cells into the lesion site.
To further clarify the role of chemokine receptors involved
in EAE, Fife et al [23] examined CCR expression in normal
(unprimed), PLP139–151 primed non-activated,
PLP139–151 primed and reactivated lymph node derived
T cells, and CNS-isolated CD4+ T cells from SJL mice
receiving PLP139–151 specific, in vitro reactivated T cells.
Normal resting CD4+ T cells and primed non-activated T
cells expressed mRNA for CCR1, CCR2, CCR3, CCR5,
CCR6, CCR7 and CCR8. In vitro activated T cells expressed
in higher amounts most of the CCRs found in normal T
cells as well as CCR4. After passive transfer of encephalito-
genic activated T cells in naïve recipients, the donor
derived encephalitogenic cells and the host-derived CD4+
T cells isolated only from the CNS lesions but not from
spleen expressed mRNA for CCR1. This latter observation
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was confirmed at protein level, and appeared to be spe-
cific for acute EAE. Neutralization of the CCR1 ligand
CCL3 (MIP-1α) diminished the inflammatory infiltrate in
the CNS.
The effects of anti-chemokine treatments in the mouse
EAE is summarized by Elhofy et al [24] and Karpus et al
[25] and is in consensus with data in the rat model.
Although various strains and protocols were used, overall
anti-RANTES (CCL5) had no effect in these models, anti-
MIP-1α (CCL3) decreased the severity of acute EAE and
anti-MCP-1 (CCL2) reduced the severity of both acute
EAE and the relapses in CR-EAE. However, it is important
noting that in some respect, these observations are model
specific. While the impact of anti-CCL5 immune treat-
ment was unremarkable in the autoantigen-induced
forms of EAE, antibody treatment targeting CCL5 in a
mouse hepatitis virus-induced inflammatory demyelina-
tion model resulted in diminished leukocyte infiltration
and reduced neurological disability [26].
Genetic manipulations of the murine model provide fur-
ther insights in the characterization of CCL / CCR mole-
cules in EAE. In mice with the CCL2 transgene under the
control of the lck (which directs the expression of trans-
gene to cortical thymocytes) or MBP promoters (which
directs the expression of transgene to the CNS), a sponta-
neous infiltration of monocytes / macrophages in the thy-
mus and CNS was observed, respectively [27]. LPS
injection induced higher CCL2 expression in the brain
and markedly enhanced the mononuclear cell (MNC)
infiltrate. The relationship between LPS treatment, CCL2
expression and MNC recruitment into the CNS remains
partially understood, and seems to involve a complex
immune regulatory mechanism rather than just a selective
effect mediated by the upregulation of the CCL2 trans-
gene. Nevertheless, these transgenic mice were clinically
normal both before and after LPS injection. More recently,
Elhofy et al [28] examined TH1 lymphocytes in a PLP-
induced EAE model using a transgenic mouse strain that
constitutively expressed low CCL2 levels in the CNS under
the control of the astrocyte-specific glial fibrillary acidic
protein promoter. CCL2 transgenic mice developed
milder EAE than the littermate controls, despite similar
numbers of CD4 and CD8 T cells in the CNS infiltrates
and an increased number of monocytes in the CNS of the
CCL2 transgenic animals. Functional studies revealed that
encephalitogenic T cells from the CCL2 transgenic mice
produced significantly less interferon-γ and proliferated
less in the presence of PLP peptides than those of the non-
transgenic controls. Increased CCL2 expression in the
CNS also resulted in a decreased IL-12 receptor expression
by PLP-specific T cells. Thus in this model, the overexpres-
sion of CCL2 in the CNS resulted in a suppression of the
TH1 response and a milder clinical phenotype of EAE,
despite the enhanced effect on monocytes.
The CCL2 knock out (-/-) mice showed resistance to EAE
and significantly decreased macrophage infiltration in the
CNS following active immunization with MOG35–55
peptide. While T cells from CCL2 (-/-) mice transferred
EAE to wild type mice, wild type T cells did not induce
EAE in CCL2 (-/-) recipient mice. These observations sug-
gest a key role for CCL2 in the recruitment of macro-
phages into the CNS and thus, in the pathogenesis of EAE
[29,30,4]. The array of ligands for CCR2 includes MCP-1
(CCL2), MCP-2 (CCL8), MCP-3 (CCL7) or MCP-5
(CCL12). As CCL2 (-/-) mice did not show a compensa-
tory upregulation of MCP-2 (CCL8), MCP-3 (CCL7) or
MCP-5 (CCL12) mRNA molecules, MCP-1 (CCL2) is
likely to be the main ligand for CCR2 in mice with EAE.
The clinical phenotype of CCR2 (-/-) genotype was similar
to that of the CCL2 (-/-) genotype, characterized by a
reduced macrophage infiltration in the spinal cord and a
decreased susceptibility to actively (MOG35–55) induced
acute EAE in the studies by Fife et al [31] and Izikson et al
[32]. T cells from CCR2 (-/-) immunized mice produced
similar levels of interferon-γ and IL2 as those from con-
trols, and were capable of transferring EAE in a naïve
recipient. In contrast, T cells from wild type mice did not
cause EAE in a CCR2 (-/-) recipient [31]. However, these
observations again appeared to be model specific. Gaupp
et al [33] reported that, even though the disease was
milder or delayed, three CCR2 (-/-) mouse strains retained
susceptibility to EAE in their experiments. Histological
analyses revealed an abundance of neutrophils in lesions
of the CCR2 (-/-) mice in contrast to the monocyte abun-
dance in EAE lesions of wild-type mice. The development
of compensatory immune mechanisms for the lack of
CCR2 was evidenced by the increased mRNA expression
for other CCL and CCR molecules (most notably IL8 and
its receptor involved in neutrophil recruitment). This
study emphasizes that promiscuity of chemokines and
their receptors may overcome the deletion of a single CCR
receptor with a resultant mild modification of the clinical
and more profound modification of the histological
phenotype.
Further studies demonstrated an approximately 50%
reduction of clinical EAE activity in the CCR1 (-/-) mice,
likely involving the altered migration of monocytes and
lymphocytes [34]. In contrast to the observed EAE sup-
pression in the CCR1 (-/-) and CCR2 (-/-) models, the
CCR5 knockout mice had the same disease severity as the
wild-type controls [35]. These studies underscore the
importance of CCR1 and CCR2 in the development of
inflammatory demyelination and give support to novel
alternative strategies targeting these CCR molecules. Such
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strategies include the development of small functional
CCR antagonists, amongst which the most significant
progress has been made with CCR1 antagonists [36,37].
CCR1 antagonist compounds were shown to inhibit
CCL3 and CCL5 induced migration of MNCs in a dose
dependent manner, and to reduce clinical EAE in rat [36-
38].
In sum, CCL and CCR data from rodent EAE models using
inbred, transgenic and knockout strains along with data
from chemokine-specific antibody treatments or CCL
DNA immunization in EAE suggest that concentration
gradients of CCL2 and CCL3 decreasing from the CNS to
the peripheral circulation are involved in the spatially and
temporally regulated recruitment of mononuclear cells
into the CNS which correlates with the course of clinical
disease. CCL2 may play a more significant role during
relapses than during the induction phase of the disease.
CCL5 is expressed by mononuclear cells in the perivascu-
lar space during the recovery phase of an acute event, and
may therefore be involved in the regulation of recovery
rather than in the initiation of the disease. In addition,
CCL19 and CCL21 are expressed by endothelial cells of
the BBB, and are involved in the strengthening of leuko-
cyte adhesion to inflamed venules followed by homing of
encephalitogenic T lymphocytes to the CNS. CCL20 can
control the recruitment of dendritic cells into lesions,
whereas CCL22 may be involved in a TH2 mediated regu-
latory process during EAE. CCL1 is likely playing an
important role in the autocrine regulation of activation of
macrophages and microglia in EAE lesions. Thus, the
functional involvement of CCL chemokines during EAE is
not only restricted to a well orchestrated recruitment of
dendritic cells, monocytes, macrophages, T effector and
regulatory cells into the CNS, but also includes a temporal
and spatial regulation of TH1 (CCL3, CCL5) or TH2
(CCL2, CCL22) polarization, and monocyte, macrophage
and microglial activation (CCL1, CCL2, CCL7, CCL8).
Their receptors, the CCRs play equally important roles in
these processes. Experimental evidence now suggests that
CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8
and CXCR3 on hematogenous mononuclear cells recog-
nize these chemoattractant and regulatory molecules to
induce cell differentiation, adhesion or migration of dis-
tinct inflammatory cells in peripheral lymphoid organs, at
the BBB and in the CNS during the course of EAE. Even
taking into consideration the complex and promiscuous
nature of the CCL – CCR network, certain pathways may
be associated with distinct biological function amenable
to intervention. Targeting CCR molecules either by mon-
oclonal antibodies or by small functional antagonists has
become a novel and realistic strategy in the treatment and
prevention of autoimmune diseases.
Multiple sclerosis
The complexity of disease pathogenesis, difficulties
accessing the site of pathology and the descriptive nature
of studies explain why the available CCL / CCR data are
less comprehensive in MS as compared to those in EAE.
Nevertheless, new observations support the generally
accepted views that MS is a predominantly TH1 lym-
phocyte mediated disease, and CCL – CCR molecules play
a significant part in the regulation of intercellular interac-
tions in the peripheral lymphoid organs, at the BBB and
in the CNS. In addition to defining chemotaxis, CCL-CCR
interactions are involved in TH1 / TH2 polarization and
regulation in MS. Recent studies also raise the possibility
that distinct molecular mechanisms with characteristic
CCL-CCR kinetics correlate with the development of his-
tological subtypes of the disease.
CCRs in the multiple sclerosis brain
A recent review of chemokines and their receptors [39]
suggests that every CC chemokine receptor (CCR1-CCR5)
interact with multiple CCLs and vice versa. Five CCRs
(CCR1, CCR2, CCR3, CCR5 and CXCR3) were detected
on infiltrating monocytes, macrophages and lymphocytes
in MS lesions. In contrast, several members of the CCL
family [CCL2 = MCP-1, CCL3 = MIP-1α, CCL4 = MIP-1β,
CCL5 = RANTES, CCL7 = MCP-3, CCL8 = MCP-2] were
expressed in astrocytes, microglia and other inflammatory
cells within MS lesions.
While control brain specimens had only scarce appear-
ance of CCR positive (microglial) cells throughout the
CNS, foamy macrophages, microglia, perivascular lym-
phocytes and occasionally, astrocytes were positive for
CCR2, CCR3 and CCR5 in chronic active plaques [39,40].
In other studies, CCR1, CCR2, CCR3 and CCR5 were
detected on mononuclear cells and macrophages in
demyelinating plaques [41,42].
Trebst et al [43] investigated the kinetics of CCR expres-
sion. In early demyelinating lesions, CCR1+/CCR5+
hematogenous monocytes and CCR1-/CCR5- microglial
cells were detected. In later stages, macrophages became
CCR1-/CCR5+, while microglia upregulated CCR5. This
observation suggest that CCR1+/CCR5+ hematogenous
monocytes enter into the CNS and stay there in the pres-
ence of appropriate ligands. During evolution of lesions,
these cells down-regulate CCR1 while retain the CCR5
expression. A more recent study [44] reveals that this dis-
tinct temporal pattern, namely the decrease in CCR1+ and
increase in CCR5+ cells, may be restricted to the histolog-
ical type II demyelinating lesions characterized by mono-
nuclear cell infiltration and immunoglobulin plus
complement deposition, and is not seen in type III lesions
characterized by oligodendrocytopathy and apoptosis
[45].
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CCR2 may also play a key role in the lesion development
based on more indirect information. CCR2 is the main,
but not exclusive, functional receptor for CCL2 [4], and as
discussed above, the CCL2 – CCR2 interaction appears to
play a key role in the development of EAE lesions. Micro-
glia, macrophages and perivascular mononuclear cells
show some degrees of immune reactivity for CCR2 in
chronic active plaques in several studies, but the expres-
sion of CCR2 is generally low in MS lesions. Nevertheless,
the data from EAE and observations in MS suggest that the
CCR2 – CCL2 interaction is important in the develop-
ment of plaques. This view was recently proposed and will
be discussed below.
CCR8, the receptor for CCL1, has been detected in vitro on
TH2 and regulatory lymphocytes, macrophages and
microglia. Using immunohistochemistry, Trebst et al [19]
detected CCR8 on phagocytic macrophages and activated
microglia in type II and type III demyelinating MS lesions.
CCR8 expression correlated with the demyelinating activ-
ity, but was not restricted to the MS pathology. Phagocytic
macrophages and activated microglia in stroke and pro-
gressive multifocal leukoencephalopathy also expressed
CCR8. Thus, CCR8 seems to identify a subset of activated
microglia in different CNS pathologies.
CCLs in the multiple sclerosis brain
Using methods of immunohistochemistry and in situ
hybridization, McManus et al [46] investigated the expres-
sion of three monocyte chemoattractant proteins, MCP-1
(CCL2), MCP-2 (CCL8) and MCP-3 (CCL7) in correlation
with the temporal evolution of plaques. All three proteins
were detected in high amounts in the center, but sharply
decreased at the edges of acute and chronic active lesions.
Hypertrophic astrocytes showed the strongest expresion,
while infiltrating mononuclear cells showed variable reac-
tivity in plaques. MCP-3 (CCL7) was also detected in the
extracellular matrix. Reactivity for these CC chemokine
ligands outside of plaques was otherwise restricted to
hypertrophic astrocytes. In situ hybridization confirmed
the observation for CCL2 at mRNA level. There seemed to
be an inverse correlation between the age of plaques and
expression of these three CCL molecules, with only a
scanty appearance of immunoreactive astrocytes in
chronic silent lesions. These methods did not detect MCP
chemokines in the brains of normal controls.
Additional studies demonstrated the expression of CCL3
and CCL4 in macrophages and microglia, and CCL3 also
in astrocytes [47-49]. CCL5 was primarily detected in
perivascular inflammatory cells and astrocytes [48-50].
While most of the above studies used the method of
immunohistochemistry, we recently assessed the mRNA
expression levels for CCL2, CCL3, CCL5, CCL7, CCL8,
CCL13 and CCL15 relative to β-actin in corresponding
normal appearing white matter (NAWM), normal appear-
ing gray matter (NAGM) and chronic active plaque con-
taining specimens from ten post mortem MS brains. These
specimens were characterized by hematoxyllin & eosin,
Luxol Fast Blue and immune staining specific for CD68
and β2-microglobulin [51]. In addition, the expression
distribution for pro- and anti-apoptotic molecules in
these specimens was also assessed by real-time PCR [51].
The selection of the above listed CC chemokines was
based on two considerations. First, we detected MS associ-
ated SNP haplotypes in the genes of CCL2, CCL11-CCL8-
CCL13, CCL15 and CCL3 [8]. Second, previous studies
suggested the involvement of CCL2, CCL7, CCL8, CCL5
and CCL3 molecules in the development of plaques
[39,46]. While neither our genetic nor our mRNA studies
revealed positive findings for CCL5, the three MCP chem-
okines CCL2 (MCP-1), CCL7 (MCP-3) and CCL8 (MCP-
2) showed altered regional expressions in MS brains. We
detected an increased expression of CCL2 in plaques as
compared to NAWMs, and an increased expression of
CCL7 in both plaques and NAWMs as compared to
NAGMs. In contrast, the expression level of CCL8 was
decreased in plaques as compared to NAWM or NAGM
specimens (Banisor and Kalman, unpublished observa-
tion). This analysis of CCL mRNA molecules in various
regions of MS brain complements the data from previous
immunohistochemical studies, and further confirms the
involvement of CCL2 and CCL7 (and possibly of CCL8)
in the development of pathology. In consensus with oth-
ers, however, we also note an increased CCL7, CCL8 and
CCL13 expression in the white matter as compared to the
gray matter in 5 other neurological disease controls (1
viral and 1 post-infectious encephalitis, 2 Alzheimer dis-
ease and 1 Parkinson disease). No differences were
observed for any of these molecules in the white and gray
matters of normal controls. We postulate that the expres-
sion of CCL molecules may be detected in various inflam-
matory conditions of the CNS, however, the temporal and
cell specific upregulation of certain CCL and CCR mole-
cules is pathology specific. Therefore, further exploration
of the expression kinetics of these molecules may facilitate
a better understanding of MS pathogenesis.
CCL and CCR detected in blood and CSF
Relatively limited numbers of studies are available regard-
ing chemokines and their receptors in the blood circula-
tion and in the cerebrospinal fluid (CSF) in MS patients.
The expression of CCR5 was found to be higher on circu-
lating T lymphocytes from MS patients than on those
from normal controls. These T cells showed an increased
migration towards CCL3 and CCL5, suggesting a func-
tional significance of the altered receptor expression
[42,52]. The migratory population represented predomi-
nantly TH1 / TH0 cells, while the non-migratory
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population was enriched for TH2 cells. The aberrant
migration of T cells towards CCL3 and CCL5 was related
to the increased expression of the CCR5 receptor, and
could be blocked by anti-CCR5 antibodies. A fluctuation
of CCR5 expression by T cells was also suggested in corre-
lation with relapses and remissions in a small group of
patients [53].
Sorensen and Sellebjerg [54] assessed the CCR expression
profile on peripheral T cells of patients with relapse,
remission or secondary progressive disease, and detected
a higher percentage of CCR2-expressing T cells in second-
ary progressive MS (SPMS) than in other patient groups.
CCR2-positive T cells displayed TH2 profile producing IL5
and tumor necrosis factor-α. The CCR5 expression associ-
ated with TH1 profile was significantly lower in SPMS
than in patients with relapsing-remitting MS (RRMS) dur-
ing relapse. Thus, the authors conclude that patients with
SPMS have a high expression of CCR2, a chemokine
receptor associated with TH2 profile, whereas patients
with RRMS preferentially display T cells with CCR5
expression and TH1 profile. More CCR5 positive T cells
produced tumor necrosis factor-α in patients with RRMS
than those in patients with SPMS. CCR2 is known to be
predominantly expressed on monocytes. However, when
expressed on T cells, CCR2 is associated with the TH2 sub-
type as CCL2 induces differentiation of T cells into TH2
phenotype [11]. While Sorensen and Sellebjerg [54]
detected significant differences in the CCR5 and CCR2
expression profile between RRMS and SPMS, they noted
no differences in CCR expression between RRMS and con-
trols. The observation regarding the association of CCR5
with RRMS is consistent with a previous study revealing
that patients with the defective CCR5 receptor (CCR5 ∆32
deletion) have prolonged relapse free periods, but the
long term prognosis of MS did not seem to correlate with
the CCR5 ∆32 genotype [55]. Besides establishing the
CCR characteristics in RRMS and SPMS, this study also
suggests that targeting the CCL2-CCR2 axis with specific
CCR2 antagonist or a combination of CCR2 and CCR5
antagonists might be an option in SPMS, whereas CCR5
antagonists alone may be considered in RRMS.
However, CCR5 on peripheral MNCs was not uniformly
found to be differentially expressed in MS subtypes [56].
MNCs from blood constitutively expressed CCL4 and
CCL5, the ligands for CCR5, in all patient groups and con-
trols. This study also failed to detect CCL2 and CCL3 by
ribonuclease protection assay in peripheral blood MNCs.
Further, the complexity of information regarding CCR5 is
reflected by a recent study suggesting the association of
the CCR5 ∆32 genotype with early death in MS [57].
There is relatively limited information available regarding
CCR and CCL expression levels in the CSF. Some investi-
gators showed that CCR5+ mononuclear cells of MS
patients were enriched in the CSF, representing a signifi-
cant proportion of monocytes and only a minority of T
cells. However, neither cell population differed quantita-
tively from those of controls, suggesting that CSF leuko-
cytes may not be fully reflective of CNS inflammation
[39,55].
Giunti et al [58] detected CCR5, CCR7 and CXCR3 posi-
tive T cells in the CSF of patients with MS and other
inflammatory neurological disease (IND) (meningitis,
encephalitis, CIDP, neuroborreliosis). Coexpression of
these receptors was noted on a subset of memory cells.
The increased ratio of CXCR3 / CCR4 was suggested as a
molecular correlate of disease activity by Nakajima et
al.[59] TH1 clones established from the CSF of patients
with IND and of controls similarly migrated in vitro
towards CXCL10, CXCL12 and CCL5. CXCL10, CXCL12
and CCL19 were increased in the CSF of these patients
[58].
Amongst CC chemokines, CCL3 and CCL5 were most
consistently found to be elevated in the CSF of MS
patients during relapses as compared to normal controls
[59-61]. In contrast, decreased CCL2 was found in the CSF
in all clinical forms of MS by Scarpini et al.[62] More con-
sistently, however, low CCL2 levels were detected only
during relapses by others [41,59,61,63,64]. The drop of
CCL2 in the CSF was not found during relapses of neuro-
myelitis optica [65]. Mahad et al [64] also found that
CCL2 in the CSF was decreased not only in patients with
MS but also in patients with IND when compared to those
of non-inflammatory CNS disease controls. In contrast,
Bartosik-Psujek and Stelmasiak [61] observed an increase
in both CCL2 and CCL5 in the CSF of patients with IND,
and suggested that the drop of CCL2 during relapses is
characteristic only of MS. Further, CCL2 concentration
increased as time from the last relapse increased and fol-
lowing corticosteroid therapy [63,64]. With the exception
of well defined changes in the CCL2, CCL3 and CCL5 lev-
els in the CSF during relapses, most investigators observed
no differences in various clinical forms of the disease
[56,61,64,66].
Pashenkov et al [67] studied two secondary lymphoid
organ chemokines, CCL19 (exodus-3, MIP-3β) and
CCL21 (exodus-2, SCL) in CSF and sera of patients with
MS, clinically isolated syndrome (CIS) presenting as optic
neuritis (ON), isolated ON, IND and non-inflammatory
neurological disease controls (NINC). CSF of the NINC
group contained CCL19 but not CCL21, while both
chemokines were elevated in the CSF of patients with MS,
CIS-ON and IND. The authors postulate that CCL19 and
CCL21 may control the retention of dendritic cells and the
recruitment of naïve T cells and activated B cells, or a de
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novo formation of lymphoid structures in plaques. These
cells are known to express CCR7, the receptor for CCL19
and CCL21. EAE studies also support the notion that
CCL19 and CCL21 play important roles both at the BBB
and in the CNS [3].
To correlate previous data on CCL concentrations in the
CSF of MS patients, Kivisakk et al [68] measured mRNA
for CCL2 / MCP-1 and CCL5 / RANTES in MNCs in the
CSF and blood of patients with MS, acute meningitis and
normal controls. While high numbers of MNCs express-
ing CCL2 and CCL5 were found in some patients, overall
no differences were observed between MS and acute men-
ingitis. This study would argue that there is no systemic
dysregulation of CC chemokines contributing to MS
pathogenesis.
In sum, the above data suggest that CCL1, CCL2, CCL3,
CCL4, CCL5, CCL7 and CCL8 are expressed by residential
glia and perivascular leukocytes in plaques. Expression of
the corresponding CCR1, CCR2, CCR3, CCR5 and CCR8
receptors has been demonstrated on infiltrating leuko-
cytes, but also on microglia, dendritic cells and astrocytes.
While the expression kinetics of CCR1 and CCR5 may dis-
criminate between histological type II and type III lesions
of MS, CCR8 is similarly expressed in both lesions types
(Table 1).
The increase of CCL3 and CCL5 in the CSF during a
relapse correlates with the increase in the expression of
their receptor, CCR5 on TH1 lymphocytes, which results
in an enhanced migratory activity of these cells towards
CCL3 and CCL5. The consistently observed decrease in
CCL2 levels in the CSF during or even prior to a relapse
generated alternative considerations. The first considera-
tion suggests, that the decreased CCL2 level likely relate to
a decreased TH2 lymphocyte activity, as CCL2 induces
TH2 polarization. Vice versa, CCL2 expression is control-
led by TH2 cytokines such as IL4. The concept of CCL2 –
TH2 coregulation is supported by the observation that
clinical improvement and normalization of the inflam-
matory CSF profile after corticosteroid treatment correlate
with the normalization of CCL2 in the CSF. Thus, meas-
urements of CCL2 in the CSF may also reflect the fluctua-
tion of TH2 activity during the course of MS. The second
consideration was proposed by Dr. Ransohoff (oral pres-
Table 1: CCR and CCL molecules in plaques, blood and CSF of MS patients. This Table summarizes in a cross-sectional manner major 
findings regarding CCR and CCL expression in brain, blood and CSF of multiple sclerosis patients. The dynamic nature of changes is 
detailed in the text. The interactions of CCL-CCR molecules on specific cell types are depicted in Figure 1. Type II and III lesions refer 
to the histological classification proposed by Lucchinetti et al [45]. References are indicated in brackets.
In chronic active plaque expressed on In blood expressed on In CSF expressed on
CCR1 Monocyte, macrophage, lymphocyte [39,41,42]
CCR2 Monocyte, macrophage, lymphocyte [39-42] TH2 in SPMS [54]
CCR3 Monocyte, macrophage, lymphocyte [39-42]
CCR4 Monocyte, macrophage, lymphocyte [39]
CCR5 Monocyte, macrophage, lymphocyte [39-42] TH1/TH0 in RRMS [42, 52-54] MNC [39,55,58]
CCR7 T, dendritic [58]
CCR8 Macrophage, microglia in type II and III lesions [19]
In early -> late stage type II lesion
CCR1+/CCR5+ -> CCR1-/CCR5+ Monocyte, macrophage [43]
CCR1-/CCR5- -> CCR1-/CCR5+ Microglia [43]
In acute, and to lesser degrees, in chronic 
active plaques expressed by
In blood expressed by In CSF
CCL2 Astrocyte, microglia, MNC [46] low in relapse [59,61,63,64]
CCL3 Astrocyte, microglia, macrophage [47-49] increased in relapse [59-61]
CCL4 Microglia, macrophage [47-49] MNC [56]
CCL5 MNC, astrocyte [48-50] MNC [56] increased in relapse [59-61]
CCL7 Astrocyte, microglia, MNC [46]
CCL8 Astrocyte, microglia, MNC [46]
CCL19 present in NIND, increased in MS, CIS-
ON, IND [67]
CCL21 increased in MS, CIS-ON, IND [67]
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entation at the ECTRIMS meeting 2004) [4,69]. This inter-
pretation reconciles the complex observations from the
EAE model suggesting a key role for CCR2 – CCL2 in the
development of inflammatory lesions, and from MS sug-
gesting a low expression of CCR2 and increased expres-
sion of CCL2 in active plaques, but a decreased CCL2 level
in the CSF. Based on this model: 1) CCL2 – CCR2 play an
important role in the development of inflammatory
demyelinating lesions both in EAE and MS; 2) CCL2
expressed in the CNS attracts CCR2+ monocytes and T
cells into the developing plaque; 3) while CCR2 binds and
internalizes CCL2 molecules in large amounts, CCL2 will
be consumed resulting in a reduced CCL2 level in the
intercellular fluids and the CSF; 4) when CCR2 encoun-
Interaction between CCL and CCR molecules at the blood-brain barrierFigure 1
Interaction between CCL and CCR molecules at the blood-brain barrier. This figure depicts CCL-CCR interactions 
at the BBB (endothelial cells and astrocytic processes) interfacing a venule and the CNS. CCL molecules (most prominently 
CCL2, CCL3, CCL7 and CCL8, but also CCL1, CCL4, CCL19 and CCL21) are produced by residential microglia, astrocytes 
and endothelial cells throughout the course of lesion development, and by infiltrating MNCs (CCL5) during late phases of 
plaque formation, and attract functionally different subsets of monocytes / macrophages, dendritic cells and T lymphocytes 
from the circulation via the BBB into the CNS. The temporal and spatial regulation of molecular events, the association of dis-
tinct CCR molecules with different histological subtypes of demyelination and the involvement of different CCL-CCR interac-
tions in T cell polarization are detailed in the text. Here we illustrate in a simplified and cross-sectional manner the main 
groups of interacting receptors on various hematogenous cells and ligands released by residential immune cells of the CNS or 
by components of the BBB. Group A of receptors and ligands expressed by and acting on monocytes / macrophages, respec-
tively: CCR1 / CCR2 / CCR3-CCL7, CCR2-CCL2, CCR3-CCL8, CCR4-CCL22; Group B of receptors and ligands expressed 
by and acting on dendritic cells, respectively: CCR4-CCL22, CCR6-CCL20, CCR7-CCL19 / CCL21; Group C of receptors and 
ligands expressed by and acting on T lymphocyes, respectively: CCR1-CCL3 / CCL5, CCR2-CCL2, CCR4-CCL22, CCR5-
CCL3 / CCL4 / CCL5, CCR7-CCL19 / CCL21, CCR8-CCL1.
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ters its ligand, the CCR2 / CCL2 complex will be internal-
ized and CCR2 will be downregulated on the surface of
inflammatory cells in the lesion.
Conclusion
Studies on EAE and MS suggest that CC chemokine lig-
ands (most prominently CCL2, CCL3, CCL5, CCL7,
CCL8, but also CCL1, CCL4, CCL19 and CCL21)
expressed by residential immune cells in the CNS or by
endothelial cells at the BBB are major chemoattractants
for hematogenic immune cells (primarily monocytes /
macrophages [CCL2, CCL7, CCL8, CCL22] dendritic cells
[CCL19, CCL20, CCL21, CCL22] and T lymphocytes
[CCL1, CCL2, CCL3, CCL4, CCL5, CCL19, CCL21,
CCL22]) via interactions with their G-protein-coupled
receptors (CCR1-CCR10). These CCL – CCR interactions
play a key role in the recruitment, activation and retention
of immune competent cells in the CNS, with the CCL1 –
CCR8, CCL2 – CCR2, CCL3 – CCR1 / CCR5, CCL5 –
CCR1 / CCR5, CCL7 – CCR1 / CCR2 / CCR3, CCL8 –
CCR3, CCL20 – CCR6, CCL19 / CCL21 – CCR7, CCL22 –
CCR4 interactions being the best characterized among
them (Figure 1). The EAE model suggests that CCL19 and
CCL21 produced by endothelial cells induce G-protein-
mediated signaling via their receptor CCR7. This signaling
leads to an enhanced adhesion of the leukocyte α4-
integrin (VLA-4) to the endothelial VCAM-1 and results in
a facilitated transmigration of leukocytes via the BBB.
CCL-CCR interactions also define the differentiation and
chemotaxis of T cell subpopulations, and thus may con-
trol the dynamic changes in the local balance of TH1
(CCL3 – CCR1 / CCR5, CCL5 – CCR1 / CCR5) and TH2
(CCL1 – CCR8, CCL2 – CCR2, CCL22 – CCR4) cell pop-
ulations in lesion. Different CCL – CCR expression kinet-
ics may characterize the different (initial, height, self-
limiting) phases and histological subtypes (type II or type
III) of inflammatory demyelination. This differential
involvement of chemokines and their receptors in various
stages and forms of MS, and the arising information con-
cerning the involvement of genetic variants of CCLs sug-
gest that small CCR antagonists may represent a realistic
strategy in controlling the inflammatory activity that may
have to be adjusted to individual disease characteristics.
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